Trial Profile
Pilot Trial To Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Girentuximab I-124 (Primary) ; Pazopanib; Sunitinib
- Indications Renal cell carcinoma
- Focus Diagnostic use
- 04 May 2023 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.
- 04 May 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2024.
- 04 May 2022 Planned End Date changed from 1 Apr 2022 to 1 Apr 2023.